Cause of Death in Patients with Lower-Risk Myelodysplastic Syndrome

Cancer

Volumn 116, Issue 9, 2010, Pages 2174-2179

  Dayyani, Farshid ^a   Conley, Anthony P ^a   Strom, Sara S ^a   Stevenson, William ^b   Cortes, Jorge E ^a   Borthakur, Gautam ^a   Faderl, Stefan ^a   O'Brien, Susan ^a   Pierce, Sherry ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cause of death; International prognostic scoring system; Mortality; Myelodysplastic syndrome

Indexed keywords

ANTIBIOTIC AGENT; GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CANCER SURVIVAL; CAUSE OF DEATH; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HEMORRHAGE; HUMANS; INFECTION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK;

EID: 77951465392     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24984     Document Type: Article

References (12)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. (Pubitemid 27132124)
2. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45-52.
3. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538-543. (Pubitemid 351386723)
4. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536-1542. (Pubitemid 46595689)
5. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106: 1794-1803.
6. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465. (Pubitemid 44511560)
7. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
8. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Cunningham I, MacCallum SJ, Nicholls MD, et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 1995; 90:602-606.
11. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008;112: 1089-1095. (Pubitemid 351304594)
12. Centers for Disease Control. Ten Leading Causes of Death, United States 2006, All Races, Both Sexes. Available at: http://webapp.cdc.gov/cgi-bin/broker. exe Accessed on May 1, 2009.